UCB Announces Commercial Availability Of Zilbrysq In U.S. To Treat Generalized Myasthenia Gravis
(RTTNews) - Biopharmaceutical company UCB announced Wednesday that ZILBRYSQ (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
ZILBRYSQ was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.
ZILBRYSQ is available by prescription as a ready-to-use pre-filled syringe that is a once-daily administration. Healthcare providers who prescribe ZILBRYSQ must enroll in the ZILBRYSQ REMS because of the risk of serious meningococcal infections.
Myasthenia gravis is a rare, chronic, autoimmune neuromuscular disease, which is characterized by muscle weakness that worsens after periods of activity and improves after periods of rest.
UCB Announces U.S. Availability Of BIMZELX To Treat Adults With Moderate-to-Severe Plaque Psoriasis
Singapore Shares May Halt Losing Streak
Japan Inflation Slows To 2.7% On Year
New Zealand Has NZ$1.185 Billion Trade Deficit
Malaysia Bourse May Reclaim 1,600-Point Level
Japan Stock Market May Extend Thursday's Gains
KOSPI In Line For Another Fresh Record High
